ArticleJournal of translational medicine2008
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".
Article in Journal of translational medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI
Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- The Applications of ELISpot in the Identification and Treatment of Various Forms of Tuberculosis and in the Cancer Immunotherapies.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.Journal for immunotherapy of cancer · 2019Review
- Are innovation and new technologies in precision medicine paving a new era in patients centric care?Journal of translational medicine · 2019Review
- The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.Seminars in cancer biology · 2018Review
- Preamble to the 2015 SITC immunotherapy biomarkers taskforce.Journal for immunotherapy of cancer · 2015Article
- A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Journal of translational medicine · 2013Article
- Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.Journal of translational medicine · 2013Article
- Cancer classification using the Immunoscore: a worldwide task force.Journal of translational medicine · 2012Review
- The immune score as a new possible approach for the classification of cancer.Journal of translational medicine · 2012Article
- Defining the critical hurdles in cancer immunotherapy.Journal of translational medicine · 2011Article
- Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment.Depression and anxiety · 2011Article
- Multiplex serum biomarker assessments: technical and biostatistical issues.Journal of translational medicine · 2011Article
- SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.Journal of translational medicine · 2011Article
- Biomarkers in T cell therapy clinical trials.Journal of translational medicine · 2011Review
- Translational Medicine is developing in China: a new venue for collaboration.Journal of translational medicine · 2011Article
- Dendritic cell subsets as vectors and targets for improved cancer therapy.Current topics in microbiology and immunology · 2011Review
- Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.Journal of translational medicine · 2010Article
- Response definition criteria for ELISPOT assays revisited.Cancer immunology, immunotherapy : CII · 2010Article
- New technologies for autoimmune disease monitoring.Current opinion in endocrinology, diabetes, and obesity · 2010Review
- Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.Cancer immunology, immunotherapy : CII · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 5 countries.
Funding
Abstract
The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.